Search Results 361-370 of 14781 for albumin

1. Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia - Mayo Clinic

   Albumin ≥ 2.5 mg/dL. Willing and able to comply with all aspects of the protocol. Provide written informed consent prior to any study-specific Screening ...

2. Probiotics Preventing Immune Checkpoint Inhibitor-Induced Colitis - Mayo Clinic

   Albumin ≥ 3 g/dL. Willing and able to provide research stool and blood samples. Negative serum pregnancy test done ≤ 7 days prior to enrollment, for women ...

3. Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects with Nonresectable or Metastatic IDH1-Mutant Cholangiocarcinoma - Mayo Clinic

   Serum albumin ≥ 2.8 g/dL. Exclusion Criteria. General Criteria. Inability to swallow oral medication. Pregnant and lactating women. WOCBP who tested positive ...

4. A Study To Evaluate The Safety And Efficacy Of Ombitasvir/ABT-450/Ritonavir And Dasabuvir In Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection And Cirrhosis - Mayo Clinic

   Albumin < 2.8 g/dL; International normalized ratio (INR) > 1.8. Participants with a known inherited blood disorder and INR > 1.8 may be enrolled with ...

5. Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC) - Mayo Clinic

   Albumin ≥ 2.8 g/dL. Adequate coagulation function defined as prothrombin time or international normalized ratio ≤ 1.5 × ULN unless the participant is ...

6. A Study To Evaluate The Impact On Metastases-free Survival With The Addition Of Saruparib Versus Placebo To A Standard Radiotherapy/androgen Deprivation Regimen In Men With High-risk Prostate Cancer With A BRCA Mutation. - Mayo Clinic

   Serum albumin ≥ 3 g/dL. INR ≤ 1.5. Participants receiving oral anticoagulants may be enrolled with an INR < 2. Participants with other causes of INR ...

7. A Study to Compare the Effectiveness, Safety and Tolerability of P1101 vs. Anagrelide for Essential Thrombocythemia - Mayo Clinic

   ... albumin >3.5 g/dL, alanine aminotransferase ≤2.0 x ULN, aspartate aminotransferase ≤2.0 x ULN at screening 11. Creatinine clearance ≥40 mL/min (by ...

8. Melanoma Clinical Trials - Mayo Clinic Research

   Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by ...

9. A Study of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) - Mayo Clinic

   Advanced PBC as defined by the Rotterdam criteria (albumin below LLN AND total bilirubin above 1 × ULN). Creatine kinase (CK) above 1.0 × ULN. eGFR below 60 ...

10. A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ - Mayo Clinic

    * Albumin \>= 3 g/dL (less than or equal to 28 days prior to registration) * Negative serum pregnancy test done =\< 7 days prior to Registration, for women ...